2012至2016年法国常规临床实践中达芦那韦在HIV-1感染者中的使用
该研究评估了2012至2016年法国三类HIV感染者使用达芦那韦的病毒学结局:初治者、治疗失败后换用者及病毒学控制后换用者。4年病毒学成功累积发生率在初治者为80.9%、失败后换用者为82.2%,控制后换用者病毒学失败累积发生率为12.6%;达芦那韦单药治疗失败风险较高。
要点
- 初治者使用达芦那韦4年病毒学成功累积发生率为80.9%。
- 治疗失败后换用达芦那韦者4年病毒学成功累积发生率为82.2%。
- 病毒学控制后换用者4年病毒学失败累积发生率为12.6%,单药治疗风险较高。
核心结论
- 含达芦那韦方案在初治、治疗失败后换用及病毒学控制后换用的HIV感染者中均获得相似的高病毒抑制率或维持病毒学成功。
研究设计与样本
- 研究评估2012至2016年法国三个HIV感染者组使用达芦那韦的病毒学结局,样本量分别为初治者3235人、失败后换用者3485人、控制后换用者3005人。
主要发现
- 初治者4年病毒学成功累积发生率为80.9%,与较低病毒载量和较高CD4细胞计数相关。
- 治疗失败后换用者4年病毒学成功累积发生率为82.2%,与较低病毒载量相关。
- 病毒学控制后换用者4年病毒学失败累积发生率为12.6%。
- 达芦那韦单药治疗病毒学失败风险较高(sHR=1.67,95%CI 1.15-2.42),双药治疗与三药及以上相比无差异(sHR=1.00,95%CI 0.71-1.42)。
关键数值与推荐
- 病毒学成功定义为血浆HIV-1病毒载量<50 copies/mL。
- 病毒学失败定义为连续两次病毒载量>50 copies/mL或一次>50 copies/mL后在下一次检测前更换治疗。
临床怎么用
- 达芦那韦可用于初治及经治HIV感染者的治疗,但应避免单药治疗以降低病毒学失败风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We assessed virological outcomes of darunavir use in France from 2012 to 2016, in three groups of people living with HIV (PLHIV): (i) antiretroviral (ARV)-naive PLHIV; (ii) ARV-experienced PLHIV switching to darunavir while failing therapy; and (iii) ARV-experienced PLHIV switching to darunavir while virologically controlled. METHODS: Virological success (VS) was defined as a plasma HIV-1 viral load (VL) <50 copies/mL and virological failure (VF) as two consecutive VL >50 copies/mL or one VL >50 copies/mL followed by a treatment switch prior to the next VL measurement. The cumulative incidence of VS was assessed considering darunavir discontinuation, loss to follow-up and death as competing risks, while estimates of cumulative incidence of VF accounted for loss to follow-up and death. RESULTS: Among the 3235 ARV-naive PLHIV initiating darunavir, the 4 year cumulative incidence of VS was 80.9% and was associated with lower VL and higher CD4 cell counts. Among the 3485 ARV-experienced PLHIV switching to darunavir while failing therapy, the 4 year cumulative incidence of VS was 82.2% and was associated with lower VL. Among the 3005 ARV-experienced PLHIV switching to darunavir while virologically controlled, the 4 year cumulative incidence of VF was 12.6%. The risk of VF was higher with darunavir monotherapy [subdistribution hazard ratio (sHR)=1.67, 95% CI 1.15-2.42] while no difference was observed with dual therapy (sHR = 1.00, 95% CI 0.71-1.42) relative to triple therapy or more. CONCLUSIONS: Darunavir-containing regimens yielded similarly high rates of viral suppression in PLHIV whether they were ARV naive or ARV experienced switching to darunavir while failing therapy, or of maintaining VS in ARV-experienced PLHIV switching to darunavir while virologically controlled.
引用
- Potard V, Canestri A, Gallien S, et al. Use of darunavir in HIV-1-infected individuals in routine clinical practice from 2012 to 2016 in France. J Antimicrob Chemother. 2019. PMID: 31384941. doi:10.1093/jac/dkz338
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。